What is Coya Therapeutics, Inc.'s (COYA) StockRank?

MoatMap's StockRank for Coya Therapeutics, Inc. (COYA) is 11/100, with a Strong Sell signal. This is a composite score combining Quality (24), Value (37), and Momentum (35) factor ranks across MoatMap's 20,000+ stock universe.

Does Coya Therapeutics, Inc. have an economic moat?

Coya Therapeutics, Inc. (COYA) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Coya Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Coya Therapeutics, Inc. (COYA) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Coya Therapeutics, Inc. in?

Coya Therapeutics, Inc. (COYA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

COYA

STRONG SELLREMOVE

Coya Therapeutics, Inc. · Healthcare · United States · $113M · Avg Vol: $865K/d

StockRank

P/E (TTM)

—

ROE

-51.3%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Micro-cap biotech focused on neurodegenerative diseases; lacks the financial strength, cash flows, and moat required for a high-conviction position.

COMPANY DESCRIPTION

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel regulatory T cell (Treg) enhancing therapies for neurodegenerative and autoimmune diseases. Its competitive edge lies in targeting the immune system's role in these complex conditions with innovative Treg-based approaches, aiming to restore immune balance. As a clinical-stage firm, its valuation is heavily tied to successful clinical trial outcomes and regulatory approvals.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	6M	4M	8M	15.1%
EPS	-4.73	-0.79	-0.98	-1.27	—
Shares	10M	14M	17M	21M	+116.3%
Debt	13M	6M	5M	7M	-18.9%
Equity	-8M	36M	40M	43M	9.9%
Op CF	-7M	-11M	-10M	-11M	—
Inv CF	-525,000	-543,186	-25,000	-1M	—
Fin CF	9M	38M	16M	20M	—

PRICE (1M)+18.6%

SMA 50SMA 200

$5.03

RSI (14)

54.8

52W High

$7.75

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-51.2%13.4

ROE

-51.3%16.9

GP/Assets

-15.4%5.7

Op. Margin

-3038.1%4.2

FCF/Assets

-19.5%17.4

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

15.02x92.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-3.0x69.4

P/FCF

—N/A

P/B

2.3x50.7

P/S

14.0x21.1

Div Yield

—N/A

Momentum

52W High %

65%48.2

RS 6M

-24%49.8

SMA 50/200

0.87x26.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-59%7.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$113M

P/E (Forward)

-2.6x

Gross Margin

-96.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COYA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
COYA	Coya Therapeutics, Inc.(you)	$113M	11	STRONG SELL
BMEA	Biomea Fusion, Inc.	$100M	10	STRONG SELL
CGTX	Cognition Therapeutics, Inc.	$107M	9	STRONG SELL
BDTX	Black Diamond Therapeutics, Inc.	$129M	14	STRONG SELL
PEPG	PepGen Inc.	$104M	7	STRONG SELL
AARD	Aardvark Therapeutics, Inc.	$92M	7	STRONG SELL
ALDX	Aldeyra Therapeutics, Inc.	$106M	5	STRONG SELL
ANIX	Anixa Biosciences, Inc.	$91M	7	STRONG SELL
CNTB	Connect Biopharma Holdings Limited	$150M	14	STRONG SELL
KLRS	Kalaris Therapeutics, Inc.	$123M	4	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

Coya Therapeutics, Inc. (COYA) — Stock Score Summary

Coya Therapeutics, Inc. (COYA) has a MoatMap StockRank of 11/100 based on Quality (24/100), Value (37/100), and Momentum (35/100) factor scores. The current signal is STRONG SELL. Micro-cap biotech focused on neurodegenerative diseases; lacks the financial strength, cash flows, and moat required for a high-conviction position.

Key Financial Metrics

Price	$5.03
Market Cap	$113M
P/E (Forward)	-2.59
Price/Book	2.27
Return on Equity	-51.3%
Return on Invested Capital	-51.2%
Gross Margin	-96.7%
Operating Margin	-3038.1%
Revenue Growth	-2.6%
Free Cash Flow	$-10M

Coya Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Coya Therapeutics, Inc.’s (COYA) StockRank?: MoatMap’s StockRank for Coya Therapeutics, Inc. (COYA) is 11/100, with a Strong Sell signal. It is a composite of Quality (24), Value (37), and Momentum (35) factor ranks across MoatMap’s 20,000+ stock universe.
Does Coya Therapeutics, Inc. have an economic moat?: Coya Therapeutics, Inc. (COYA) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Coya Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Coya Therapeutics, Inc. (COYA) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Coya Therapeutics, Inc. in?: Coya Therapeutics, Inc. (COYA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).